A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
Open Access
- 20 December 2010
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (4), 574-582
- https://doi.org/10.3324/haematol.2010.033456
Abstract
Background Multiple myeloma is a plasma-cell tumor with heterogeneity in molecular abnormalities and treatment response. Design and Methods We have assessed whether human myeloma cell lines have kept patients’ heterogeneity using Affymetrix gene expression profiling of 40 human myeloma cell lines obtained with or without IL6 addition and could provide a signature for stratification of patient risk. Results Human myeloma cell lines, especially those derived in the presence of IL6, displayed a heterogeneity that overlaps that of the patients with multiple myeloma. Human myeloma cell lines segregated into 6 groups marked by overexpression of MAF, MMSET, CCND1, FRZB with or without overexpression of cancer testis antigens (CTA). Cell lines of CTA/MAF and MAF groups have a translocation involving C-MAF or MAFB, cell lines of groups CCND1-1 and CCND1-2like have a t(11;14) and cell lines of group MMSET have a t(4;14). The CTA/FRZB group comprises cell lines that had no or no recurrent 14q32 translocation. Expression of 248 genes accounted for human myeloma cell line molecular heterogeneity. Human myeloma cell line heterogeneity genes comprise genes with prognostic value for survival of patients making it possible to build a powerful prognostic score involving a total of 13 genes. Conclusions Human myeloma cell lines derived in the presence of IL6 recapitulate the molecular diversity of multiple myeloma that made it possible to design, using human myeloma cell line heterogeneity genes, a high-risk signature for patients at diagnosis. We propose this classification to be used when addressing the physiopathology of multiple myeloma with human myeloma cell lines.Keywords
This publication has 50 references indexed in Scilit:
- TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell linesHaematologica, 2007
- Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression ProfilingCancer Research, 2007
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- Induction of Multilineage Markers in Human Myeloma Cells and Their Down-Regulation by Interleukin 6International Journal of Hematology, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.2006
- Microarray‐based understanding of normal and malignant plasma cellsImmunological Reviews, 2006
- IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3Biochemical and Biophysical Research Communications, 2005
- Cancer/testis antigens, gametogenesis and cancerNature Reviews Cancer, 2005